DiagnaMed Holdings Corp. announced that it has been accepted into the Hamilton Ecosystem to Accelerate and Leverage Trials of Health Innovation program to accelerate the clinical research and commercialization efforts in Canada for the Company's CERVAI Brain Health AI Platform. The HEALTHI program, established in partnership with the National Research Council of Canada Industrial Research Assistance Program, Innovation Factory and the Synapse Consortium, will assist the Company in developing relationships with world-class clinicians and hospital facilities before the commercialization of CERVAI in Canada's leading research hospitals, such as Hamilton Health Sciences and St.

Joe's Healthcare Hamilton. Based on research and development at Drexel University and the University of Miami, CERVAI combines a Brain Age?? Estimation and Brain Health Assessment tool with the aim to ' raise a red flag' for potential brain health issues.

CERVAI can assess if a brain is aging more quickly or more slowly than is typical for healthy individuals. Brain age is estimated by collecting neural activity data of the brain with a low-cost and easy-to-use electroencephalogram ("EEG") headset and calculating the data with a proprietary machine-learning model. In addition, CERVAI??

can assess if a person has a healthy brain or is in the early stage of cognitive decline. Brain health is scored by taking a clinically validated assessment for brain resilience, vulnerability and performance functions. Individuals can seek out personalized diagnostics and interventions, such as medication or lifestyle changes, that may help to decrease the development or progression of cognitive decline.

The CERVAI?? Brain Health commercial test pilot program is available to clinics in the U.S. and Canada. Ideal clinics for the pilot program must focus on health and wellness, sports and physical therapy, mental health, chropractic care, or clinical research for neurological and cognitive disorders.